Crossmark

Efficacy, safety, and exploratory biomarker analysis of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: a prospective, single-arm, phase II trial

Crossref DOI link: https://doi.org/10.1186/s12916-025-04385-4

Published Online: 2025-10-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhao, Xiao

Zhang, Jing

Qiu, Lupeng

Han, Quanli

Yan, Xiang

Zhu, Yanyun

Wang, Jinliang

Zhang, Xiaoling

Jiao, Shunchang

Sun, Shengjie
License Information

Text and Data Mining valid from 2025-10-06

Version of Record valid from 2025-10-06
More Information

Article History

Received: 19 March 2025

Accepted: 9 September 2025

First Online: 6 October 2025

Declarations

:

: This trial was approved by the Ethics Committee of Chinese PLA General Hospital (S2020-466–01), and conducted in accordance with the Declaration of Helsinki, good clinical practice (GCP) guidelines, and applicable local regulations. All patients provided consent for data collection and analysis.

: None.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below